Genesco Q1 Sales Dip 5.8%, Net Loss Widens to $17.5M
Ticker: GCO · Form: 10-Q · Filed: Jun 12, 2025 · CIK: 18498
| Field | Detail |
|---|---|
| Company | Genesco INC (GCO) |
| Form Type | 10-Q |
| Filed Date | Jun 12, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Retail Footwear, Q1 Earnings, Sales Decline, Net Loss, Journeys, Johnston & Murphy, Schuh
TL;DR
**GCO's Q1 results are a red flag; Journeys is dragging them down, and investors should be wary.**
AI Summary
GENESCO INC (GCO) reported net sales of $447.2 million for the first quarter ended May 3, 2025, a decrease of 5.8% from $474.7 million in the prior-year quarter. The company experienced a net loss of $17.5 million, or $1.56 per diluted share, compared to a net loss of $10.7 million, or $0.97 per diluted share, in the same period last year. Journeys Group's comparable sales decreased by 6%, while Johnston & Murphy Group's comparable sales declined by 9%. Schuh Group, however, saw a 2% increase in comparable sales. Gross margin improved to 48.7% from 48.1% in the prior year, primarily due to lower promotional activity at Journeys and improved product margins at Johnston & Murphy. Selling, general, and administrative expenses increased by 1.1% to $219.7 million, driven by higher marketing and technology costs. The company's strategic outlook includes managing inventory levels and optimizing store performance, particularly within the Journeys segment, which continues to face headwinds.
Why It Matters
Genesco's widening net loss and declining sales, particularly at its flagship Journeys brand, signal significant challenges in a competitive retail footwear market. This performance could impact investor confidence, potentially leading to further stock price volatility. Employees at underperforming Journeys stores may face job insecurity as the company optimizes its retail footprint. For customers, this could mean fewer store locations or changes in product offerings as Genesco attempts to streamline operations and improve profitability. The broader market will watch to see if Genesco can adapt to changing consumer preferences and intense competition from online retailers and larger chains like Foot Locker and DSW.
Risk Assessment
Risk Level: high — The company reported a net loss of $17.5 million for Q1 2025, a significant increase from the $10.7 million net loss in Q1 2024. Net sales decreased by 5.8% to $447.2 million, indicating declining demand across key segments like Journeys (-6% comparable sales) and Johnston & Murphy (-9% comparable sales), which points to substantial operational and market risks.
Analyst Insight
Investors should consider reducing exposure to GCO given the widening net loss and continued sales declines in core segments. Monitor future filings for signs of successful turnaround strategies, particularly for the Journeys Group, before considering any new positions.
Financial Highlights
- revenue
- $447.2M
- net Income
- -$17.5M
- eps
- -$1.56
- gross Margin
- 48.7%
- revenue Growth
- -5.8%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Journeys Group | -6% | |
| Johnston & Murphy Group | -9% | |
| Schuh Group | 2% |
Key Numbers
- $447.2M — Net Sales Q1 2025 (Decreased 5.8% from $474.7M in Q1 2024)
- -$17.5M — Net Loss Q1 2025 (Widened from -$10.7M in Q1 2024)
- -$1.56 — Diluted EPS Q1 2025 (Worse than -$0.97 in Q1 2024)
- -6% — Journeys Comparable Sales (Significant decline in key segment)
- -9% — Johnston & Murphy Comparable Sales (Steep decline in another core segment)
- 2% — Schuh Comparable Sales (Only segment showing positive comparable sales growth)
- 48.7% — Gross Margin Q1 2025 (Improved from 48.1% in Q1 2024 due to lower promotions)
- $219.7M — SG&A Expenses Q1 2025 (Increased 1.1% due to higher marketing and technology costs)
Key Players & Entities
- GENESCO INC (company) — filer of the 10-Q
- Journeys Group (company) — segment with 6% comparable sales decrease
- Johnston & Murphy Group (company) — segment with 9% comparable sales decrease
- Schuh Group (company) — segment with 2% comparable sales increase
- $447.2 million (dollar_amount) — net sales for Q1 2025
- $474.7 million (dollar_amount) — net sales for Q1 2024
- $17.5 million (dollar_amount) — net loss for Q1 2025
- $10.7 million (dollar_amount) — net loss for Q1 2024
- $1.56 (dollar_amount) — diluted EPS for Q1 2025
- $0.97 (dollar_amount) — diluted EPS for Q1 2024
FAQ
What were Genesco's net sales for the first quarter of 2025?
Genesco's net sales for the first quarter ended May 3, 2025, were $447.2 million, representing a 5.8% decrease compared to $474.7 million in the prior-year quarter.
How did Genesco's net income change in Q1 2025?
Genesco reported a net loss of $17.5 million, or $1.56 per diluted share, for Q1 2025. This is a widening of the net loss compared to $10.7 million, or $0.97 per diluted share, in Q1 2024.
Which Genesco segments experienced sales declines in Q1 2025?
The Journeys Group saw a 6% decrease in comparable sales, and the Johnston & Murphy Group experienced a 9% decline in comparable sales during Q1 2025.
Did any Genesco segments show sales growth in Q1 2025?
Yes, the Schuh Group was the only segment to report positive growth, with a 2% increase in comparable sales for the first quarter of 2025.
What caused the improvement in Genesco's gross margin?
Genesco's gross margin improved to 48.7% in Q1 2025 from 48.1% in Q1 2024, primarily due to lower promotional activity at Journeys and improved product margins at Johnston & Murphy.
What were the key drivers behind the increase in Genesco's SG&A expenses?
Selling, general, and administrative expenses for Genesco increased by 1.1% to $219.7 million in Q1 2025, mainly driven by higher marketing and technology costs.
What is Genesco's strategic outlook for the near future?
Genesco's strategic outlook includes managing inventory levels and optimizing store performance, particularly within the Journeys segment, which continues to face market headwinds.
What are the main risks highlighted by Genesco's Q1 performance?
The main risks include continued declining sales in core segments like Journeys and Johnston & Murphy, a widening net loss, and the challenge of adapting to a competitive retail environment.
How might Genesco's Q1 results impact investors?
Genesco's Q1 results, with a widening net loss and declining sales, could negatively impact investor confidence and potentially lead to further stock price volatility for GCO.
What is the overall financial health of Genesco based on this 10-Q?
Based on this 10-Q, Genesco's financial health appears challenged, marked by declining net sales, a widening net loss, and significant comparable sales decreases in its largest segments, despite a slight improvement in gross margin.
Risk Factors
- Declining Comparable Sales in Key Segments [high — market]: Journeys Group comparable sales decreased by 6% and Johnston & Murphy Group by 9% in Q1 2025. This indicates significant challenges in core revenue-generating segments, potentially impacting overall financial performance.
- Increased SG&A Expenses [medium — operational]: Selling, general, and administrative expenses rose by 1.1% to $219.7 million, driven by higher marketing and technology costs. This increase, despite declining sales, puts pressure on profitability.
- Inventory Management Challenges [medium — market]: The company's strategic outlook includes managing inventory levels, suggesting potential overstocking or slow-moving inventory issues. This can lead to increased holding costs and markdowns.
- Store Performance Optimization [medium — operational]: Focus on optimizing store performance, particularly within the Journeys segment, highlights potential underperforming locations or operational inefficiencies that need addressing.
- Widening Net Loss [high — financial]: The company reported a net loss of $17.5 million in Q1 2025, a widening from a $10.7 million loss in the prior year. This deterioration in profitability is a key concern.
Industry Context
Genesco operates in the highly competitive footwear and accessories retail sector. The industry is influenced by changing fashion trends, consumer spending habits, and the ongoing shift towards e-commerce. Key players compete on brand recognition, product assortment, pricing, and customer experience across physical and digital channels.
Regulatory Implications
As a publicly traded company, Genesco is subject to SEC regulations and reporting requirements, including timely filing of 10-Q and 10-K reports. Compliance with accounting standards (GAAP) and disclosure rules is critical to avoid penalties and maintain investor confidence.
What Investors Should Do
- Monitor comparable sales trends in Journeys and Johnston & Murphy
- Analyze SG&A spending efficiency
- Evaluate inventory management strategies
- Assess the turnaround potential of Journeys Group
Glossary
- Comparable Sales
- A measure of sales performance that compares sales in a reporting period to sales in a prior period, excluding stores that have been opened or closed during that time. (Crucial for understanding the underlying sales trends of existing stores within each segment, as reported for Journeys, Johnston & Murphy, and Schuh.)
- Gross Margin
- The difference between revenue and cost of goods sold, expressed as a percentage of revenue. It indicates profitability before operating expenses. (Improved to 48.7% from 48.1%, showing better pricing power or cost control on merchandise sold.)
- SG&A Expenses
- Selling, General, and Administrative expenses represent the costs incurred in the normal course of business operations, excluding the cost of goods sold. (Increased by 1.1% to $219.7 million, driven by marketing and technology investments, impacting the bottom line.)
- Net Sales
- The total revenue generated from sales after deducting returns, allowances, and discounts. (Decreased by 5.8% to $447.2 million, indicating a contraction in overall business activity.)
- Diluted EPS
- Earnings Per Share calculated by dividing net income by the weighted average number of outstanding common shares, including the dilutive effect of stock options and other potential common shares. (Worsened to a loss of $1.56 per share from $0.97 in the prior year, reflecting the increased net loss.)
Year-Over-Year Comparison
Compared to the prior year's first quarter, Genesco Inc. reported a 5.8% decrease in net sales, falling to $447.2 million. The company also saw a widening net loss, increasing from $10.7 million to $17.5 million, and a corresponding decline in diluted EPS from -$0.97 to -$1.56. While gross margin saw a slight improvement to 48.7% due to reduced promotional activity, SG&A expenses increased by 1.1%, indicating rising operational costs that are pressuring profitability amidst declining revenues.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on June 12, 2025 regarding GENESCO INC (GCO).